Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

1.

Short communication: Effectiveness at 48 weeks of switching from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV type 1-infected patients in a Brazilian cohort.

Westin MR, Biscione F, Ribeiro KM, Greco DB, Tupinambás U.

AIDS Res Hum Retroviruses. 2014 Feb;30(2):113-7. doi: 10.1089/AID.2013.0084. Epub 2013 Aug 14.

PMID:
23875625
[PubMed - indexed for MEDLINE]
2.

Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.

De Castro N, Braun J, Charreau I, Pialoux G, Cotte L, Katlama C, Raffi F, Weiss L, Meynard JL, Yazdanpanah Y, Delaugerre C, Madelaine-Chambrin I, Aboulker JP, Molina JM; EASIER ANRS 138 study group.

Clin Infect Dis. 2009 Oct 15;49(8):1259-67. doi: 10.1086/605674.

PMID:
19757993
[PubMed - indexed for MEDLINE]
Free Article
3.

Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.

Gallien S, Braun J, Delaugerre C, Charreau I, Reynes J, Jeanblanc F, Verdon R, de Truchis P, May T, Madelaine-Chambrin I, Aboulker JP, Molina JM; EASIER ANRS 138 Study Group.

J Antimicrob Chemother. 2011 Sep;66(9):2099-106. doi: 10.1093/jac/dkr269. Epub 2011 Jun 28.

PMID:
21712241
[PubMed - indexed for MEDLINE]
Free Article
4.

Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of life.

Grant PM, Palmer S, Bendavid E, Talbot A, Slamowitz DC, Cain P, Kobayashi SS, Balamane M, Zolopa AR.

J Clin Virol. 2009 Dec;46(4):305-8. doi: 10.1016/j.jcv.2009.09.025. Epub 2009 Oct 12.

PMID:
19819183
[PubMed - indexed for MEDLINE]
5.

Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study.

Towner W, Klein D, Kerrigan HL, Follansbee S, Yu K, Horberg M.

J Acquir Immune Defic Syndr. 2009 Aug 1;51(4):367-73. doi: 10.1097/QAI.0b013e3181ae35de.

PMID:
19487951
[PubMed - indexed for MEDLINE]
6.

Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: a follow-up study.

Passaes CP, Guimarães ML, Cardoso SW, Pilotto JH, Veloso V, Grinsztejn B, Morgado MG.

J Med Virol. 2012 Dec;84(12):1869-75. doi: 10.1002/jmv.23409.

PMID:
23080489
[PubMed - indexed for MEDLINE]
7.

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.

Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ Jr, Chung J, DeMasi R, Donatacci L, Drobnes C, Delehanty J, Salgo M; TORO 1 Study Group.

N Engl J Med. 2003 May 29;348(22):2175-85. Epub 2003 Mar 13. Erratum in: N Engl J Med. 2003 Sep 11;349(11):1100.

PMID:
12637625
[PubMed - indexed for MEDLINE]
Free Article
8.

Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression.

Santos JR, Llibre JM, Ferrer E, Domingo P, Imaz A, Moltó J, Martin-Iguacel R, Caum C, Podzamczer D, Clotet B.

HIV Clin Trials. 2009 Nov-Dec;10(6):432-8. doi: 10.1310/hct1006-432.

PMID:
20133273
[PubMed - indexed for MEDLINE]
9.

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.

Lazzarin A, Clotet B, Cooper D, Reynes J, Arastéh K, Nelson M, Katlama C, Stellbrink HJ, Delfraissy JF, Lange J, Huson L, DeMasi R, Wat C, Delehanty J, Drobnes C, Salgo M; TORO 2 Study Group.

N Engl J Med. 2003 May 29;348(22):2186-95.

PMID:
12773645
[PubMed - indexed for MEDLINE]
Free Article
10.

Decreases in inflammatory and coagulation biomarkers levels in HIV-infected patients switching from enfuvirtide to raltegravir: ANRS 138 substudy.

Silva EF, Charreau I, Gourmel B, Mourah S, Kalidi I, Guillon B, De Castro N, Caron F, Braun J, Molina JM; ANRS 138 EASIER Study Group.

J Infect Dis. 2013 Sep;208(6):892-7. doi: 10.1093/infdis/jit280. Epub 2013 Jun 24.

PMID:
23801606
[PubMed - indexed for MEDLINE]
Free Article
11.

A cohort study of enfuvirtide immunological and virological efficacy in clinical practice.

Bienvenu B, Krivine A, Rollot F, Pietri MP, Lebault V, Meritet JF, Guerin C, Spiridon G, Salmon D, Guillevin L, Lebon P, Launay O.

J Med Virol. 2006 Oct;78(10):1312-7.

PMID:
16927284
[PubMed - indexed for MEDLINE]
12.

Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen.

Harris M, Larsen G, Montaner JS.

AIDS. 2008 Jun 19;22(10):1224-6. doi: 10.1097/QAD.0b013e328302f3b5.

PMID:
18525270
[PubMed - indexed for MEDLINE]
13.

Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.

Nelson M, Arastéh K, Clotet B, Cooper DA, Henry K, Katlama C, Lalezari JP, Lazzarin A, Montaner JS, O'Hearn M, Piliero PJ, Reynes J, Trottier B, Walmsley SL, Cohen C, Eron JJ Jr, Kuritzkes DR, Lange J, Stellbrink HJ, Delfraissy JF, Buss NE, Donatacci L, Wat C, Smiley L, Wilkinson M, Valentine A, Guimaraes D, Demasi R, Chung J, Salgo MP.

J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):404-12.

PMID:
16280694
[PubMed - indexed for MEDLINE]
14.

Switching from a toxicity-causing antiretroviral to enfuvirtide in patients with HIV: the SWITCH TOX study.

Streinu-Cercel A, de Gorgolas M, Müller M, Portilla J, Rugina S, Böcher W, Staszewski S, Pulik P, Rowell L, Salgo M, Stoll M.

HIV Clin Trials. 2008 Nov-Dec;9(6):375-86. doi: 10.1310/hct0906-375.

PMID:
19203903
[PubMed - indexed for MEDLINE]
15.

Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo).

Joly V, Fagard C, Grondin C, Descamps D, Yazdanpanah Y, Charpentier C, Colin de Verdiere N, Tabuteau S, Raffi F, Cabie A, Chene G, Yeni P; S 130 Apollo Trial Group.

Antimicrob Agents Chemother. 2013 Feb;57(2):758-65. doi: 10.1128/AAC.01662-12. Epub 2012 Nov 19.

PMID:
23165467
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and safety at 24 weeks in a Montreal cohort.

Talbot A, Machouf N, Thomas R, Marcotte S, Therrien R, Lessard B, Dufresne S, Lalonde R.

J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):362-4. doi: 10.1097/QAI.0b013e3181aa1398. No abstract available.

PMID:
19553775
[PubMed - indexed for MEDLINE]
17.

Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.

[No authors listed]

Prescrire Int. 2008 Aug;17(96):135-7.

PMID:
19480091
[PubMed - indexed for MEDLINE]
18.

A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy.

Lalezari JP, Eron JJ, Carlson M, Cohen C, DeJesus E, Arduino RC, Gallant JE, Volberding P, Murphy RL, Valentine F, Nelson EL, Sista PR, Dusek A, Kilby JM.

AIDS. 2003 Mar 28;17(5):691-8.

PMID:
12646792
[PubMed - indexed for MEDLINE]
19.

Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients.

Ruof J, Dusek A, DeSpirito M, Demasi RA.

Clin Drug Investig. 2007;27(7):469-79.

PMID:
17563127
[PubMed - indexed for MEDLINE]
20.

Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: the ALLIANCE Study.

Dwyer DE, Workman C, Hales G, Amin J, Cooper D, Miller J; Alliance Study Group.

Antivir Ther. 2006;11(4):409-19.

PMID:
16856614
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk